Targeted breast cancer drug capivasertib has received MHRA approval in the UK. The go-ahead is the outcome of a multi-collaborative approach by AstraZeneca in conjunction with Astex Pharmaceuticals – and Astex’s collaboration with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited. It follows similar licensing by the US Food and Drug Administration in November 2023, and approval in April by the European Medicines Agency (EMA). Dr Harren Jhoti, Astex’s CEO, said: “We are incredibly proud that our drug discovery partnerships have resulted in such a successful outcome, …
